Richard Finn, MD

Highlights from the MONALEESA-2 and -3 trials combining frontline ribociclib with endocrine therapy in patients with HR+/HER2- metastatic breast cancer.

Time-to-chemotherapy results of the PALOMA-2 and -3 trials in HR+/HER2- metastatic breast cancer, which combined frontline palbociclib and endocrine therapy.

Shared insight on how best to select frontline therapy, alone or in combination, for patients with HR+/HER2- mBC.

Expert Harold Burstein, MD, PhD, breaks down the treatment armamentarium for patients with HR+/HER2- metastatic breast cancer.

Massimo Cristofanilli, MD, FACS, provides a historical overview of the HR+/HER2- metastatic breast cancer (mBC) treatment landscape.

Richard S. Finn, MD, discusses treatment considerations for patients with hepatocellular carcinoma.

Richard Finn, MD, associate professor of medicine, University of California, Los Angeles David Geffen School of Medicine, discusses the role of lenvatinib in the treatment of patients with liver cancer.

Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma.

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses results of the RESOURCE study in advanced liver cancer.

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses studies of pembrolizumab (Keytruda) in patients with previously untreated hepatocellular carcinoma (HCC).

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the promise of regorafenib (Stivarga) for the treatment of hepatocellular carcinoma (HCC), as seen in the phase III RESORCE trial.

Richard Finn, MD associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses what’s next for palbociclib following the PALOMA trials.